NATIONAL PHYSICIAN GROUPS, PATIENTS AND ADVOCATES URGENTLY CALL FOR PROVINCIAL COVERAGE OF “LIFE-CHANGING” EPILEPSY TREATMENT
21 nov. 2024 10h00 HE
|
Canadian Epilepsy Alliance
Toronto, Ontario, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The Canadian Epilepsy Alliance, national physician groups representing neurologists, epileptologists and other healthcare professionals, patients...
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
21 nov. 2024 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Nov. 21, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
[Latest] Global Epilepsy Treatment Devices Market Size/Share Worth USD 787.3 Million by 2033 at a 4.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
19 nov. 2024 11h30 HE
|
Custom Market Insights
Austin, TX, USA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Epilepsy Treatment Devices Market Size, Trends and Insights By Product Type...
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
19 nov. 2024 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Crossject démontre à nouveau la facilité d’utilisation de son auto-injecteur ZENEO® dans une nouvelle étude en conditions extrêmes
13 nov. 2024 11h30 HE
|
CROSSJECT
Crossject achève avec succès une nouvelle étude américaine de facteurs humains visant à évaluer la facilité d'utilisation ZENEO® Midazolam, qui sera bientôt commercialisé à l'échelle mondiale sous...
Crossject’s ZENEO® Auto-Injector's usability further demonstrated in extreme HAZMAT conditions
13 nov. 2024 11h30 HE
|
CROSSJECT
Crossject successfully completes a new U.S. summative human factors study to assess the usability of ZENEO® Midazolam, soon to be commercialized globally as ZEPIZURE®, under simulated chemical...
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
13 nov. 2024 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
06 nov. 2024 16h12 HE
|
Catalyst Pharmaceuticals, Inc.
Reports Q3 2024 Total Revenues of $128.7 Million, Representing a 25.3% YoY Increase Record Revenues Driven by Continued Organic Growth in its Rare Disease Franchise Robust Financial Performance...
Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
22 oct. 2024 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset
21 oct. 2024 00h00 HE
|
Angelini Pharma
Angelini Pharma Enters Into Exclusive Option Agreement With Cureverse to License Global Development & Commercialization Rights
For Brain Health Asset